Full Fiscal Year Pharmaceutical Software and Services Revenues Up 20.9%;
Earnings per share of $0.33, up 14.9% over prior year
Simulations Plus Reports Preliminary Revenues for Fourth Quarter and Fiscal Year 2017
Company Reports Record Fourth-Quarter and Full-Year Revenues
Simulations Plus Releases MembranePlus™ Version 2
Major update incorporates new models and tighter integration with GastroPlus™
DILIsym Services Inc., a Simulations Plus Company, Releases DILIsym® Version 6A
Significant update of liver safety program includes performance and capability enhancements
Simulations Plus Sets Date for 3rd Quarter 2017 Earnings Release and Conference Call
Conference Call to be on Monday, July 10, 2017, at 4:15 PM ET
Simulations Plus Reports Third Quarter FY2017 Financial Results
Record quarter as revenues grow 12.2%, 9MoFY17 net income up 11.4%
Dr. Daniel Weiner Joins Simulations Plus Board of Directors
World-renowned scientist, FDA consultant, and experienced manager to reinforce SLP board
Simulations Plus to Acquire DILIsym Services, Inc.
Accretive acquisition to expand Simulations Plus offerings by adding leading provider of drug-induced liver injury (DILI) software and consulting services
Simulations Plus Reports Second Quarter FY2017 Financial Results
Record second quarter as revenues grow 10.5%, 6MoFY17 net income up 13.6%
Simulations Plus Finalizes Distributor Agreement With Korean Company
Local sales channel should lead to further penetration of domestic Korean pharmaceutical market